[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Recently a number of therapies have been reported on the treatment efficacy for glucocorticoid-induced osteoporosis (GIOP) . Especially, bisphosphonates have been proven to have both prevention and treatment of GIOP by large-scale randomized double-blinded placebo controlled studies and recommended the use of them as a first line therapy by treatment guideline in many countries. On the other hand, activated vitamin D(3) analogues also have been reported the effectiveness of GIOP although the effect is lower than bisphosphonates. Vitamin K(2) analogues suggested to have the efficacy in treatment of GIOP in Japan. This article reviews the evidence of treatment efficacy of current treatment especially bisphosphonates in patients with GIOP.
Sato
Shinji
S
Keio University School of Medicine, Department of Internal Medicine.
D019386:Alendronate / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D024482:Vitamin K 2 / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D024482:Vitamin K 2; D002762:Cholecalciferol; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate